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Abstract
Background: Studies of drug utilization in patients with diabetes, a chronic disease that can be treated with a wide
range of available medicines, have attracted substantial social and clinical interest.
Objective: To characterize antidiabetic medicine consumption between 2005 and 2017, to evaluate the trends of
these medicines in mainland Portugal, and to compare district consumption. An additional objective was to
perform a statistical analysis on drug consumption in different regions of Portugal.
Methods: A descriptive, longitudinal observational study; the setting was mainland Portugal ( excluding Azores and
Madeira).
Each medicine has a respective defined daily dose (DDD). The sum of the DDD, provides the annual consumption
in terms of the DDD for each district each year. When calculating the annual average for the resident district
population and the number of days in a year, the denominator is expressed as 1000 inhabitants per day (TID).
Main outcome measure: The DDD/TID for mainland Portugal (for all districts) between 2005 and 2017 for
antidiabetic medicines.
Information was obtained from the official database of prescription medicine invoices with reimbursement in
mainland Portugal.
Results: In mainland Portugal, the antidiabetic medicine consumption was 49.3 DDD/TID in 2005 and 88.2 DDD/
TID in 2017. The consumption of insulins and their analogs increased from 10.8% to 17.4% compared to the total
consumption of antidiabetic medicines.
In 2017, the level of biguanide consumption was 23.1 DDD/TID, that of sulphonylurea consumption was 15.8 DDD/
TID, that of DPP-4 inhibitor consumption was 6.8 DDD/TID, and that of SGLT2 inhibitor consumption was 3.0 DDD/
TID. The oral consumption of fixed-dose combinations reached 21.4 DDD/TID.
After employing a geographical division between north and south and between coastal and inland regions, the
consumption of several different drugs showed statistically significant differences.
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Conclusions: When comparing 2017 with 2005, the panorama was quite different, with higher levels of consumption
of antidiabetic medicines, insulins and their analogs, noninsulin medicines, long-acting and fast-acting insulins and
their analogs, metformin, DPP-4 inhibitors and, mainly, metformin combined with a DPP-4 inhibitor. The SGLT2
inhibitors achieved a representative consumption.
Different consumption patterns may be related to sociodemographic factors or to clinical practices.
Keywords: Diabetes Mellitus, Insulin, Hypoglycemic agents, Drug utilization, Portugal
Background
In 1977, the World Health Organization (WHO) defined
the concept of drug utilization as the marketing, distri-
bution, prescription, and use of drugs in a society [1].
Drug utilization has medical, social, and economic con-
sequences. In 2003, the WHO published guidelines on
drug utilization research, and in addition to their useful-
ness, highlighted the importance of these studies [2].
Numerous drug utilization studies examining the
methodological aspects have been published [3–9]. In
this context and as diabetes is a chronic disease, diabetes
is appropriate for the application of this type of study.
However, few studies have been published in this field.
The high level of prevalence is verified based on the
information released by the Organization for Economic
Cooperation and Development (OECD) that highlights
an age-standardized diabetes prevalence of 6.0 % for the
population aged 18–99 years old in 28 European coun-
tries and 9.9 % for Portugal using data collected in 2017
[10]. The Portuguese National Diabetes Observatory
(OND) report showed a prevalence of diabetes of 13.3 %
for 2015 in the 20-79-year-old population, which in-
cludes an estimated prevalence of 5.8 % for undiagnosed
individuals in the same population [11]. We should bear
in mind that diabetes prevalence data includes diabetes
mellitus type 1 and 2, with diabetes mellitus 1 represent-
ing 5–10 % of existing cases and diabetes mellitus type 2
accounting for 90–95 % [12].
The recommendations for the treatment of type 1 dia-
betes mellitus in Portugal propose different insulin
therapeutic regimens [13], which incorporate the scien-
tific evidence available for insulin therapy. The recom-
mendations for the treatment of type 2 diabetes mellitus
propose different therapeutic regimens. In Portugal, the
main documents on this matter are the recommenda-
tions of the Portuguese Society of Diabetology (SPD)
[14–16] and the Clinical Guidelines of the Portuguese
General Directorate of Health (DGS) [17–19], which in-
corporate the scientific evidence available for a wide
range of antidiabetic drugs. The general approach to
treat a patient with type 2 diabetes mellitus is the follow-
ing: metformin is the first-line treatment; when a patient
is not adequately controlled with metformin, a second
noninsulin medication may be added; this second
medication may be a sulphonylurea, a dipeptidyl
peptidase-4 (DPP-4) inhibitor or a glitazone and, in the
more recent guidelines, a glucagon-like peptide-1 (GLP-
1) analog or a sodium-glucose cotransporter 2 (SGLT2)
inhibitor. If even with this combined medication, the pa-
tient is not glycemic controlled, it is possible to add a
third antidiabetic drug from other classes of noninsulin
drugs. However, in every stage, if the patient presents a
high level of glycated hemoglobin (> 10 %) [17, 19], ther-
apy with insulin should be started.
Insulin is the only treatment available for type 1 dia-
betes mellitus, but due to the low prevalence of this dis-
ease, we can consider that consumption fluctuations for
this drug are essentially related to type 2 diabetes melli-
tus. The consumption of noninsulin medicines is related
to the treatment of type 2 diabetes mellitus.
Drug utilization studies in diabetes concerning the con-
sumption of antidiabetic medicines often do not differenti-
ate between the types of diabetes. Drug utilization studies
on the consumption of medicines are usually expressed as
prevalence, or exposition, of those drugs in a population.
It can be the population of a country (e.g., Denmark [20])
or a region or other specific area (e.g., Granada metropol-
itan area of Andalusia region, Spain [21]).
In addition to analyzing the consumption of antidia-
betic drugs, these studies provide insights into the effects
of successive therapeutic guidelines and the introduction
of new therapeutic classes of antidiabetic drugs into the
market in clinical practice. The results can also provide
valuable information for the rational use of medicines
and allow decision-making regarding the policy for
medicines.
The aim of this study was to characterize antidiabetic
medicine consumption between 2005 and 2017, to
evaluate the trends of these medicines in mainland
Portugal, and to compare district consumption. An add-
itional objective was to perform statistical analysis of the
consumption of these drugs in different regions of
Portugal.
Methods
This study was observational, descriptive, and longitu-
dinal; the setting was mainland Portugal (excluding
Azores and Madeira).
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All medicines, including antidiabetic medicines, were
categorized according to the fifth level code of the Ana-
tomical Therapeutic Chemical Classification System
(ATC). For each ATC, there is a respective defined daily
dose (DDD). All DDD units were reported in accordance
with the ATC/DDD guidelines for implementation in
2018 [22]. Knowing the total units of DDD of a medicine
for each year and each district, we obtained the con-
sumption of that medicine for all 18 Portuguese districts
from 2005 to 2017.
If the DDD units were for a specific district and a re-
spective year, it was necessary to divide the DDD units
by the annual average resident population in that district
[23] and by the number of days depending on the spe-
cific year, considering the leap years. To express the
DDD per thousand inhabitants per day (TID), it is ne-
cessary to multiply this value by 1000.
Consequently, it is possible to calculate the DDD/TID
of mainland Portugal for a specific medicine using the
total DDD consumption in all districts and the total resi-
dent population using the data of all districts.
From the fifth to the fourth second level of the ATC
code, the DDD/TID ratios were calculated consecutively
from sum totals of the respective DDD values for the
group of drugs belonging to the fourth level of the ATC
code for the district population and respective year. The
same procedure was applied to each group of drugs for
the third ATC level, in accordance with their
categorization in the group of insulins and their analogs
or to the group of noninsulin antidiabetic drugs. Finally,
for the second ATC level, the DDD/TID was calculated
for antidiabetic drugs.
The main outcome measure was the DDD/TID for
mainland Portugal (including for all districts), between
2005 and 2017, for antidiabetic medicines, for insulins
and analogs (including the different types of insulins),
and for noninsulin medicines (including the different
types of noninsulin medicines).
The average levels of consumption of antidiabetic
drugs, insulins and their analogs, and noninsulin antidia-
betic drugs were calculated using the method described
below to compare geographical areas that were larger
than districts. All the districts were grouped into two
categories (see Fig. 1) to identify the group of districts
from the north and south, in addition to the group of
districts from the coastal and inland regions. The north
group included the districts most representative of the
North and Central Health Regions, and the south group
included the districts most representative of the Lisbon
and Tagus Valley, Alentejo and Algarve Health Regions.
Fig. 1 District names and groups categorized into north/south and coastal/inland classifications
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Therefore, two groups that jointly, contained all the dis-
tricts of mainland Portugal were obtained. The coastal
group included the districts along the Atlantic strip, ex-
cept for the Beja district, as it is essentially inland; all the
remaining districts, including the Beja district, were in-
cluded in the inland group.
The database used for this study was provided by
Infarmed (Portuguese Medicines Authority). The data-
base was created as a result of the reconciliation of in-
voices sent by community pharmacies to the Health
Service’s Central Management (ACSS) for subsidized
drugs in mainland Portugal. All antidiabetic drugs in
Portugal are subsidized by the National Health Service
irrespective of their income as long as they are either
Portuguese or residing in Portugal. Patients obtain medi-
cation at community pharmacies by presenting a phys-
ician prescription. Community pharmacies are spread all
over mainland Portugal, covering all districts, therefore
allowing patients easy access to antidiabetic medicines.
ACSS is not responsible for the invoice reconciliation
for the Azores and Madeira regions; therefore, the data-
base only has data for mainland Portugal.
The database contained the total DDD units for each
antidiabetic medicine, according to the fifth level code of
the ATC for the respective district (18 districts) and the
respective year (between 2005 and 2017). For the oral
fixed-dose combination drugs, the database did not in-
clude the annual DDD units. Instead, it contained the
number of tablets consumed, for each of these medi-
cines, per district and year. This information allowed the
calculation of the annual DDD units for each oral fixed-
dose combination drug.
The arithmetic calculations were performed using
Microsoft Office Excel 2007 software and the statistical
calculations, including the Mann-Whitney U test, were
performed using SPSS (v25) software. The level of statis-
tical significance was set to p < 0.05, with a 95 % confi-
dence interval (CI).
Results
Table 1 presents the consumption of antidiabetic drugs,
insulins and their analogs, and noninsulin antidiabetic
drugs, including all types of these medicines, reported in
DDD/TID from 2005 to 2017.
The consumption of antidiabetic drugs increased from
49.3 DDD/TID in 2005 to 88.2 DDD/TID in 2017, indi-
cating an annual average growth rate of 6.6 %.
Insulins and their analogs, with a consumption of 5.3
DDD/TID in 2005 and 15.4 DDD/TID in 2017 exhibited
an annual average growth rate that was greater than the
increase in the consumption of antidiabetic drugs.
Table 1 The consumption of antidiabetic drugs in DDD/TID, from the second ATC level to the fourth ATC level, between 2005 and
2017
ATC Medicines 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
DDD/TID
A10 Antidiabetics 49.3 52.3 55.4 60.8 64.6 67.8 70.2 73.6 78.9 82.2 84.4 86.0 88.2
A10A Insulins and analogues 5.3 6.9 7.7 8.6 9.2 10.1 10.9 11.8 13.1 13.9 14.4 15.0 15.4
A10B Non-insulin antidiabetics 44.0 45.4 47.7 52.2 55.4 57.7 59.3 61.7 65.8 68.3 69.9 71.0 72.9
A10A Insulins and analogues
A10AB Fast-acting insulins 1.0 0.9 1.2 1.6 1.9 2.2 2.6 3.0 3.4 3.7 3.9 4.1 4.3
A10AC Intermediate-acting insulins 3.0 3.1 3.5 3.5 3.1 3.0 2.7 2.5 2.4 2.4 2.3 2.1 2.0
A10AD Combined-acting insulins 1.4 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 2.9 2.8 2.6
A10AE Long-acting insulins < 0.1 < 0.1 < 0.1 0.5 1.1 1.8 2.6 3.3 4.1 4.8 5.3 5.9 6.4
A10B Non-insulin antidiabetics
A10BA Biguanides 12.8 13.5 14.9 17.4 18.0 17.7 18.0 19.2 20.9 22.1 22.6 23.0 23.1
A10BB Sulphonylureas 24.9 23.7 23.2 22.3 21.0 19.7 18.5 18.8 19.2 18.8 17.8 16.7 15.8
A10AF α-glucosidase inhibitors 3.4 3.3 3.2 3.0 2.7 2.4 2.1 1.9 1.7 1.5 1.2 1.0 0.8
A10BG Glitazones 0.2 0.2 0.6 1.0 1.0 1.1 1.1 1.0 0.9 0.8 0.6 0.5 0.5
A10BH DPP-4 inhibitors - - > 0.1 2.4 3.6 3.8 4.1 4.4 4.9 5.6 6.1 6.5 6.8
A10BJ GLP-1 analogues - - - - - - - - - 0.3 0.8 1.0 1.2
A10BK SGLT2 inhibitors - - - - - - - - - < 0.1 1.0 2.0 3.0
A10BX Other non-insulin antidiabetics 0.3 0.5 0.6 0.6 0.6 0.5 0.5 0.4 0.4 0.3 0.3 0.2 0.2
A10BD Oral fixed-dose combinations 2.4 4.1 5.1 5.3 8.5 12.4 15.0 16.0 17.9 18.9 19.5 20.3 21.4
Note: The results presented in Table 1 were rounded to the first decimal place. The authors performed all calculations with raw data. Therefore, calculating annual
growth rates with Table 1 data may lead to slightly different results than those presented in the text of this article
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Ultimately, insulins and their analogs represented 17.4 %
of the total consumption of antidiabetic drugs.
The consumption of noninsulin antidiabetic drugs was
44.0 DDD/TID in 2005 and increased to 72.9 DDD/TID
in 2017. The increase in consumption slowed between
2014 and 2017, with an annual average growth rate of
2.2 %. If noninsulin antidiabetic drugs represented 89.2 %
of the total antidiabetic drugs consumed in 2005, their
representativity decreased to 82.6 % in 2017.
Insulins and their analogs (ATC fourth level)
Between 2014 and 2017, the consumption of long-acting
insulins exhibited an annual average increase of 11.7 %.
Furthermore, fast-acting insulins, despite the less
marked variation, followed the trend of long-acting insu-
lins. In 2017, these two types of insulin represented
70.1 % of the total insulin consumed.
In 2014, the combined-acting insulins represented of
22.1 % of the total insulin consumption. However, in 2017,
this percentage decreased to 16.9 %. The intermediate-acting
insulins, which were the most frequently consumed type of
insulin in 2005, with a representativity of 56.7 % of all insu-
lins, displayed a decrease in consumption that was accom-
panied by an increase in the consumption of other insulins
and displayed a relative consumption of 13.0 % in 2017.
Noninsulin antidiabetic drugs (ATC fourth level)
From 2005 to 2017, the consumption of biguanides in-
creased from 12.8 to 23.1 DDD/TID, achieving first place
in this group of noninsulin drugs. From 2014 to 2017, the
consumption of sulphonylureas decreased annually, on
average by 5.3 %. In 2017, the value remained at 15.8
DDD/TID. In 2017, the consumption of DPP-4 inhibitors
reached 6.8 DDD/TID, representing an annual average
growth rate of 7.3 % between 2014 and 2017.
In 2017, α-glucosidase inhibitors, glitazones, and a
group of other noninsulin antidiabetic drugs (nateglinide)
were consumed at lower levels in descending order.
In 2017, the consumption of new medicine classes,
glucagon-like peptide-1 (GLP-1) analogs and sodium-
glucose cotransporter 2 (SGLT2) inhibitors, reached 1.2
and 3.0 DDD/TID, respectively.
Oral fixed-dose combinations
Oral fixed-dose combinations experienced an annual
average growth rate of 78.0 % between 2005 and 2014
and 4.5 % between 2014 and 2017. In 2017, these combi-
nations achieved an impressive consumption level of
21.4 DDD/TID, which represents 29.4 % of noninsulin
antidiabetic drugs (Fig. 2).
In 2005, oral fixed-dose combinations were practically
represented by metformin combined with sulphonylurea,
with a representativity of 95.2 %. However, with the de-
crease in the absolute level of consumption of this
combination and the emergence and increased con-
sumption of metformin combined with a DPP-4 inhibi-
tor, the first combination represented 2.1 % and the
second combination represented 92.6 % of the consump-
tion of this drug class in 2017.
Notably, in 2017, the consumption of metformin and
DPP-4 inhibitors reached 23.1 and 6.8 DDD/TID, re-
spectively. However, in the same year, the consumption
of metformin in combination with a DPP-4 inhibitor
was 19.8 DDD/TID.
Among the new class of medicines, the consumption of
metformin in combination with an SGLT2 inhibitor was
0.8 DDD/TID in 2017. This value achieved second place
in the consumption of oral-fixed dose combinations.
District-level variations
In 2017, the districts with the highest levels of consump-
tion of antidiabetic drugs were Bragança (109.9 DDD/
TID) and Vila Real (107.8 DDD/TID), and the districts
with the lowest levels of consumption were Faro (69.1
DDD/TID) and Lisbon (76.4 DDD/TID). From 2014 to
2017, the greatest increase in consumption occurred in
the Bragança district, with an annual average increase of
4.2 %, and the lowest consumption was observed in Beja,
with an annual average decrease of 1.8 % (Fig. 3: map A).
In 2017, the districts with the highest levels of con-
sumption of insulins and their analogs were Coimbra
(21.6 DDD/TID) and Castelo Branco (21.1 DDD/TID),
and the districts with the lowest levels of consumption
were Lisbon (13.1 DDD/TID) and Braga (13.3 DDD/
TID). From 2014 to 2017, the greatest increase in con-
sumption occurred in the Évora district, with an annual
average increase of 4.8 %, and the lowest consumption
occurred in Coimbra, with an annual average increase of
1.4 % (Fig. 3: map B).
In 2017, the districts with the highest levels of con-
sumption of noninsulin antidiabetic drugs were Vila Real
(92.7 DDD/TID) and Bragança (90.8 DDD/TID), and the
districts with the lowest levels of consumption were Faro
(55.7 DDD/TID) and Lisbon (63.3 DDD/TID). From
2014 to 2017, the greatest increase in consumption oc-
curred in the Bragança and Viana do Castelo districts,
both with an annual average increase in consumption of
3.7 %, and the lowest consumption was observed in Beja,
with an annual average increase of 0.7 % (Fig. 3: map C).
Northern/southern and coastal/inland district
comparisons
The average consumption of antidiabetic drugs in the
northern districts was 52.6, 89.3, and 96.9 DDD/TID in
2005, 2014, and 2017, respectively, and the values in the
southern districts were 52.7, 86.9, and 90.2 DDD/TID in
2005, 2014, and 2017, respectively.
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The average consumption of insulins and their analogs
in the northern districts was 6.2, 15.8, and 17.3 DDD/
TID in 2005, 2014, and 2017, respectively, and 5.3, 13.5,
and 15.1 DDD/TID in the southern districts in 2005,
2014, and 2017, respectively.
The average consumption of noninsulin antidiabetic
drugs in the northern districts was 46.4, 73.4, and 79.6
DDD/TID in 2005, 2014, and 2017, respectively, and
47.5, 71.4, and 75.2 DDD/TID in the southern districts
in 2005, 2014, and 2017, respectively.
In the division between northern and southern dis-
tricts, the difference between the average levels of con-
sumption of antidiabetic drugs, insulins and their
analogs, or noninsulin antidiabetics never achieved stat-
istical significance in any year, except for insulins and
their analogs in 2014 (Mann-Whitney U test: p = 0.020).
The average consumption of antidiabetic drugs in the
coastal districts was 49.0, 80.6, and 87.3 DDD/TID in
2005, 2014, and 2017, respectively, and 56.3, 96.2, and
101.3 DDD/TID in the inland districts in 2005, 2014,
and 2017, respectively. In each year analyzed, the average
consumption of antidiabetic drugs in the coastal districts
was always lower than that of the inland districts, indi-
cating that these differences were statistically significant
(Mann-Whitney U test: p = 0.019, p < 0.001, p = 0.001,
respectively, for each year).
The average consumption of insulins and their analogs
in the coastal districts was 5.5, 14.3, and 15.7 DDD/TID
in 2005, 2014, and 2017, respectively, and 6.2, 15.5, and
17.1 DDD/TID in the inland districts in 2005, 2014 and
2017, respectively. In each year of observation, the aver-
age consumption of insulins and their analogs in the
coastal districts was always lower than that in the inland
districts. However, none of these differences were statis-
tically significant.
The average consumption of noninsulin antidiabetic
drugs in the coastal districts was 43.5, 66.7, and 71.6
DDD/TID in 2005, 2014, and 2017, respectively, and
50.1, 78.5, and 84.2 DDD/TID in the inland districts in
2005, 2014, and 2017, respectively. In each year ana-
lyzed, the average consumption of noninsulin antidia-
betics in the coastal districts was always lower that in
the inland districts, and these differences were statisti-
cally significant (Mann-Whitney U test: p = 0.014, p =
0.001, p = 0.003, respectively, for each year).
Discussion
The data enable a multifaceted discussion, regardless of
whether the results were obtained per se or whether they
were attributed to any relationship with diabetes.
The analysis of the period between 2005 and 2017,
representing 13 years of data, provides information on
the overall trends and evolution of consumption for a
reasonable period. However, due to the availability of
new antidiabetic drugs and their inclusion in two guide-
lines published in 2013 and 2015 [15, 16], the period be-
tween 2014 and 2017 was highlighted in the results and
the discussion.
In the period analyzed, 2005 to 2017, the consumption
of antidiabetic drugs, insulins and their analogs, and
noninsulin antidiabetic drugs was characterized by con-
sistent growth, as shown in other studies [24, 25]. Not-
ably, the proportion of consumption of insulins to
noninsulin drugs also increased. The growth in the con-
sumption of these medicines may be explained by an in-
creasing number of people diagnosed with type 2
Fig. 2 Consumption of oral fixed-dose combinations
Moura et al. BMC Endocrine Disorders           (2021) 21:30 Page 6 of 10
diabetes mellitus and by the fact that nonglycemic-
controlled type 2 diabetes mellitus patients started being
treated with an increasing number of noninsulin antidia-
betic drugs or even accepting the use of insulin.
Consulting the OECD statistics for the total consump-
tion of antidiabetic drugs reported in DDD/TID [26],
per county, which includes data from 28 countries in
2017, Portugal is in 14th place in descending order (68.1
DDD/TID) between Belgium (71.0 DDD/TID) and South
Korea (66.9 DDD/TID). Based on the results obtained
from the present study (88.2 DDD/TID), Portugal would
be the second country after Finland (92.1 DDD/TID) in
Fig. 3 Consumption of drugs - a antidiabetics, b insulins and their analogs, and c noninsulin antidiabetics
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terms of consumption. The likely explanation for the dif-
ference between the findings of this study and the
OECD statistics is that the national authority database
does not include the consumption of oral fixed-dose
combination drugs in DDD, as explained in the
methods section.
The consumption of insulins and their analogs increased
substantially. From 2005 to 2014, their consumption in-
creased at a high rate, and their consumption increased at
a lower rate from 2014 to 2017. The sharp increase in the
consumption of long-acting and, to a lesser extent, fast-
acting insulins is very significant. In 2017, the situation
was very different from the value of approximately 6
DDD/TID observed in 2000 [27]. The same trend has
been observed in Denmark, where an increase in the num-
ber of users of insulins and their analogs, including fast-
acting insulins, was observed from 1999 to 2014, and a
substantial increase in the number of users of long-acting
insulins was observed from 2004 to 2014 [20]. The same
trend was observed in the Granada region of Spain in a
study examining data collected from 2001 to 2014 [21].
At the end of the period analyzed here, the consump-
tion of metformin exceeded the consumption of sulpho-
nylureas, without considering the combination with a
DPP-4 inhibitor. From a different perspective, a study
performed in France revealed the same trend [28]. In
2006, 58 % of the patients initiating type 2 diabetes mel-
litus treatment with noninsulin antidiabetic drugs
started with metformin as the first-line treatment, while
34 % initiated treatment with sulphonylureas. This differ-
ence increased significantly at the end of the study in
2013; 80 % started with metformin and 15 % were first
with sulphonylureas.
The increase in the use of insulins and metformin is
consistent with the clinical guidelines [14–19]. Of
course, with some delay, these successive guidelines
exerted a positive effect on the consumption of insulins
and metformin over time. For example, a consistent de-
crease in sulphonylurea consumption and a consistent
increase in metformin consumption were observed
throughout the period studied, as metformin consump-
tion only exceeded sulphonylurea consumption in 2012.
Surprisingly, the relative consumption of the fixed-
dose combination of metformin with a DPP-4 inhibitor
was higher than that of DPP-4 inhibitors alone. A rele-
vant reference to the substantial consumption of DPP-
4 inhibitors is the study by C. Torre et al. [29]. This
study compares consumption in Portugal and the
Netherlands based on data from 2013. In the
Netherlands, DPP-4 inhibitors are less than 5 % of the
total noninsulin antidiabetic drugs consumed, and fixed-
dose combinations are consumed at residual levels.
Based on our study, for the same year, the consumption
of the fixed-dose combination of metformin with a DPP-
4 inhibitor was 16.3 DDD/TID (corresponding to 24.8 %
of noninsulin antidiabetic drugs), while DDP-4 inhibitor
consumption was 4.9 DDD/TID (corresponding to 7.3 %
of noninsulin antidiabetic drugs). Compared with the
Netherlands, we concluded that Portugal exhibited sub-
stantial consumption of these drugs. Notably, the OECD
reports an age-standardized diabetes prevalence of 4.6 %
for the population aged 18–99 years in the Netherlands
and 9.9 % in Portugal based on data collected in 2017
[10]. However, this last aspect does not explain the dif-
ference in consumption of this class of drug and its
combination with metformin between the two countries.
Most likely, these findings are related to differences in
the clinical practice between Portugal and the
Netherlands.
Returning to the topic of the consumption of a fixed-
dose combination of metformin with a DPP-4 inhibitor
and the high values observed in Portugal, the consump-
tion of these drugs increased to 25.7 % in 2014 in rela-
tion to the total consumption of noninsulin antidiabetic
drugs. In the same year, the value was 12.2 % for the
Granada region [21]. Therefore, compared to this last
study, these fixed-dose combination drugs are consumed
at very high levels in Portugal.
Based on the data collected in the last few years, the
consumption of the new medicine classes of GLP-1 ana-
logs and SGLT2 inhibitors is expected to increase in the
next few years.
The estimated prevalence of diabetes in 2015 was
13.3 %, and the estimated prevalence of diagnosed dia-
betes was 7.5 % [11]. Using the diagnosed population, an
average daily consumption by individuals with diabetes
of 1.12 DDD was obtained. We believe that this param-
eter is interesting, and a comparison of the consumption
in different countries or regions would be useful, as this
analysis would consider the population with diabetes in-
stead of the total population.
Regarding the consumption of antidiabetic drugs, insu-
lins and their analogs, or noninsulin drugs, at the district
level, looking at the distribution per quartile, there were
many changes in the positions on the years analyzed
(2005, 2014, and 2017). In this way, it is interesting to
observe, for each district, the dynamics for long-term
(2005 versus 2014 and 2005 versus 2017) and medium-
term (2014 versus 2017) relative changes in the con-
sumption of these medicines.
Previous studies have observed differences in the con-
sumption of antidiabetic drugs in different regions of
Portugal [24, 25]. In Italy, substantial differences in the
consumption of antidiabetic drugs were also observed at
the regional level; higher levels of consumption were ob-
served in the south that in the north [30].
When comparing the consumption of antidiabetic
drugs and noninsulin drugs between north and south
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districts, the differences were not statistically significant.
Concerning insulins and their analogs, although con-
sumption in the northern districts was always higher
than that in the southern districts, the results were sta-
tistically significant for only 2014. It is difficult to explain
the reason for this last result, but it is probably related
to several different factors.
Concerning the comparison of the consumption of in-
sulins and their analogs between coastal and inland dis-
tricts, there were no statistically significant differences in
any of the years analyzed, but the average consumption
was always higher in the inland districts. For the con-
sumption of antidiabetic drugs and noninsulin drugs, the
consumption was always higher in the inland districts,
and these differences were statistically significant for all
years under analysis (2005, 2014, and 2017). Inland dis-
tricts have a larger elderly population, which probably
explains the results obtained.
The concept of consumption in the market is not
completely consistent with the concept of taking the
drug. This study enabled us to characterize the levels
of exposure of a population to a drug or groups of
drugs, as well as their long-term fluctuations, and es-
tablish comparisons between these exposure levels in
populations from different geographical areas. Never-
theless, we reasonably concluded that antidiabetic
drugs are essentially consumed by people with dia-
betes, as other therapeutic indications and off-label
uses are very rare. In this study, the limitations prin-
cipally arise from the source of information. The data
do not allow us to analyze the relationship between
market consumption and the variables of the patient
(its characterization, including HbA1c levels, years of
diagnosed diabetes mellitus type 2, diabetes complica-
tions, etc.) or of the prescriber (prescriber characteris-
tics such as age, medical specialty, type of medical
institution, etc.).
The monetary values of the total outpatient drug mar-
ket of 78.1 % in 2014 and 74.9 % in 2017 corresponded
to the Health Service outpatient drug market [31]. How-
ever, all antidiabetic medicines are reimbursed by health
services. Therefore, an important aspect to consider re-
garding the origin of the database is that the market
value for insulin and noninsulin antidiabetic drugs re-
ported in 2011 by the outpatient Health Service in rela-
tion to the total outpatient market value of these same
drugs corresponded to 96.5 % [32]. This value reflects an
approximately global representativity of the antidiabetic
drugs in the outpatient market.
Conclusions
The main results reveal a consistent increase in the con-
sumption of antidiabetic drugs, insulins and their ana-
logs, noninsulin drugs, long-acting and fast-acting
insulins, metformin, DPP-4 inhibitors, and fixed-dose
combinations of metformin with a DPP-4 inhibitor.
At the end of the period examined in the present
study, the new classes of antidiabetic medicines, particu-
larly SGLT2 inhibitors, achieved a representative con-
sumption level.
In mainland Portugal, the regional differences in the
consumption of antidiabetic drugs or their subtypes are
marked by a geographical division between the coastal
and inland districts rather than by a geographical div-
ision between the northern and southern districts. In
this regional comparison, the consumption of several
different drugs reached statistical significance.
The main contribution of this article is that it provides
insights for future research analyzing the effects of
changes in the consumption of antidiabetics on the
treatment of the population with diabetes.
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